Life | Buy My IOU - Sell Your Government IOU For CASH

From Startup Dreams to a Cubicle Life

June 11th, 2011 Comments off

While entrepreneurship students get MBAs with the goal of launching a startup, many make corporate pit stops before they go into business for themselves
BusinessWeek.com — Small Business

Categories: Business Tags: Cubicle, dreams, from, Life, StartUp

Tony Hayward Gets His Life Back

May 27th, 2011 Comments off

The former head of BP is launching a new venture in the oil business
BusinessWeek.com — Finance

Categories: Investing Tags: Back, Gets, Hayward, Life, Tony

Combining Long-Term Care with Life Insurance

May 20th, 2011 Comments off

The insurance industry is building demand for products that pair long-term care with traditional life insurance, drawing down the death benefit to fund care
BusinessWeek.com — Finance

Categories: Investing Tags: Care, Combining, insurance, Life, LongTerm

You Bet Your Life 3

March 19th, 2011 50 comments

You Bet Your Life Quiz Show

Every Saturday Cambria Park.. hit us if yall wanna battle
Video Rating: 4 / 5

Categories: Economy Tags: Life

Medical news on PWRM, TEVA, and LIFE

March 11th, 2011 Comments off

Medical news on PWRM, TEVA, and LIFE

{image}

Medical news on PWRM, TEVA, and LIFE

Free Online Articles Directory

ABAnswers

0 && $ .browser.msie ) {
var ie_version = parseInt($ .browser.version);
if(ie_version

via

Hello

Password

Lost ?

Home Page > Business > Medical news on PWRM, TEVA, and LIFE

Medical news on PWRM, TEVA, and LIFE

Edit Article |

Posted: Aug 06, 2010 |Comments: 0
|

crwefinancelogo2

signup3m

POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM) is now available for .0321 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

PWRM is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3′s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, and to identify protein biomarkers and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) recently reported that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm. In connection with this approval and following the Commission’s review of this transaction, Teva made certain limited commitments, which are anticipated to have only a marginal effect on the combined companies’ activities. Teva now plans to close the transaction in the near future. Teva was represented before the European Commission by Willkie Farr & Gallagher LLP.

TEVA is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 35,000 people around the world and reached .9 billion in net sales in 2009.

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. LIFE systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of .3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference.

LIFE reported their results for its second quarter ending June 30, 2010. Their Non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as ,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading shares for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Retrieved from “http://www.articlesbase.com/business-articles/medical-news-on-pwrm-teva-and-life-2980259.html”

(ArticlesBase SC #2980259)

Need more traffic? No problem. Publish with us and see why everyone’s talking about Articlesbase.com
Liked this article? Click here to publish it on your website or blog, it’s free and easy!

Justin -
About the Author:

Questions and Answers

Ask our experts your Business related questions here…

Ask

200 Characters left

How internet can influence in our day to day life?in what ways internet is applied in the field like railways,air ticket booking system,medical service and education?
My daughter is being approved for SSI, has never worked. She has turned 18 years and completely disabled and life support. She should be eliigible for Medi Cal. Is it state medical, or Federal?
Is this sentence grammatically correct? Heterosexual couples have the right to make medical decisions for their spouse in case of hospitalization or incapacitated or if life- or- death decisions need

Rate this Article

1
2
3
4
5

0

Feedback

Print

Re-Publish

Source: http://www.articlesbase.com/business-articles/medical-news-on-pwrm-teva-and-life-2980259.html

Article Tags:
healthcare, medical, nasdaq life, nasdaq teva, otc bb pwrm

Updates of PROT, and MNTA LIFE

March 10th, 2011 Comments off

Updates of PROT, and MNTA LIFE
{Image}
Updates of PROT, and LIFE MNTA ABAnswers s 0 & & $ . Browser.msie) {var = ie_version parseInt ($ browser.version). If (ie_version Log in to register E-Mail

Remind me to forget you I

Home> Companies> updates for PROT, MNTA and updates for LIFE PROT, and MNTA LIFE | Posted on:? August 9 2010 | Comments: 0 |]]> Wed crwefinancelogo2

signup3m

Proteonomix Inc. (OTC BB: PROT), a company specializing in stem cell therapies for diabetes and cardiac injury focused planning, research into the future with the introduction of a new platform for growing human stem cells free of pollutants, to serve as a catalyst for bringing possible treatments on the market. Working with top scientists and institutions around the world, Proteonomix also working to dramatically increasing donor-recipient match rate by introducing a cord blood bank, which uses proprietary technology. cord blood stem cells have already been recognized as a possible therapy for more than 80 diseases, a number that continues to grow.

PROT is a biotechnology company based on the development of therapeutics based on the use of human cells and their derivatives. Proteoderm, Inc., a wholly owned subsidiary of Proteonomix that recently launched its retail website has opened and Proteoderm.com begun to accept pre-orders for its anti-aging skin care products. StromaCel, Inc. ‘s objective of the development of therapeutic modalities for the treatment of cardiovascular diseases (CVD). StromaCel, Inc.’ s licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix operating subsidiary. The Sperm Bank of New York, Inc. is a fully functional tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to translation of promising scientific research in stem cell biology and cell therapy to clinical applications of regenerative . Proteonomix intends to focus Medicine to create and dedicate a daughter, each of their technologies

Momenta Pharmaceuticals Inc.. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, which it recently reported its financial results for the quarter ended 30 June 2010. For the second quarter of 2010, the Company reported a net loss of .0 million, compared to a net loss of $ .8 million for the same period last year. On June 30, 2010, the company had cash and marketable securities of .7 million, compared to 7 million at 31 December 2009.

Revenues for the second quarter of 2010 was .8 million, compared with .6 million for the same period last year. The decline was a reduction of eligible expenses with our production program is M356 and a reduction of the eligible costs with our enoxaparin sodium injection program as ANDA review nearing completion refers.

Research and development expenses increased in the second quarter of 2010 were .8 million, compared to .7 million for the same period last year. The decline in research and development costs resulting from a reduction in principle production, process development and third-party research costs to support our M356 program and clinical development costs through the completion of our M118 Phase 2a study in June 2009.

MNTA is a biotechnology company based in Cambridge, MA headquarters, specializing in the detailed structural analysis of complex mixture drugs. Momenta’s technology is the development of generic versions of complex drugs, as well as on the discovery and development of novel drugs.

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology companies with tools for improving the human condition LIFE systems, supplies and services enable researchers to accelerate scientific discovery, in order discoveries and developments that make life better. . Life Technologies customers their work on the biological spectrum of work, to personalized medicine, advance regenerative science, molecular diagnostics, agricultural and environmental research and forensic science of the 21st century. Life Technologies achieved a turnover of 3 billion in 2009, employs approximately 9,000 people, has a presence in over 160 countries and has a rapidly growing copyright protection in the form of some 3,900 patents and exclusive licenses. Life Technologies was produced by the combination of Invitrogen Corporation and Applied Biosystems Inc., both in vitro diagnostics and research only by-products identified. For more information on how we make a difference.

LIFE reported their results for the second quarter ended 30 June 2010. your non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million for the second quarter of 2009 reported. before Excluding currency effects and impact of acquisitions and disposals, sales grew organically in the first quarter by 6 percent over the same period last year.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Sign up FREE Daily Stock Alerts From CRWEFinance. com / signup

THIS IS NOT A recommendation to buy or sell securities

Disclaimer: Never in any stock on our website or e-mail if you can afford it, your entire invest losing investment can presented. CRWEFinance.com publishers and their subsidiaries and contractors are not registered investment advisers or broker / dealer registered. Our disclaimer is to be read and fully understood before you read our website, our newsletter or joining our E-mail . List Release of Liability: By using this site or use the View, you acknowledge and CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and / or agents harmless and fully release from all liability to keep for any losses (monetary or otherwise), damage (monetary or not) to come to you. (read more) Rule 17B requires disclosure of payments for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has twenty thousand dollars in bar and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertising for Proteonomix, Inc. (PROT obtained. OB)

from “http://www.articlesbase.com / business-articles/updates-from-prot-mnta-and-life-2997298.html “

(ArticlesBase SC # 2997298)

articles to Articlesbase.com, and watch your . to increase traffic, click here to make it happen like this article please click here to post it on your website or blog, free, and easy Justin – the author.?:

]]> Questions and Answers Ask our expert your business question here … Ask 200 characters left stem cells is an example of how biotechnology and what are the treatments, the enzyme in immune cells theraphy Like a person’s life is affected by sickle cell anemia? Rate this article 1 2 3 4 5 Vote (s) 0 vote (s) Feedback Print E-mail to publish again Source: business-articles/updates-from-prot-mnta-and-life-2997298.html Article Tags: biotechnology, cell therapies, life Nasdaq, Nasdaq mnta OTC BB prot Related Videos Latest Business Articles More by Justin Second Life – How do I create a shadow Cell object

Second Life step by step instructions: Learn how to make a cell shaded object in Second Life (5.18) <. / p> learn more about DNA: The Cell’s Life Pattern Learn more about DNA

. The Cell’s Life Pattern in this educational video from dizzo95 (1.23)

Find the love by a Mobile plans

Jill is thrown by her boyfriend and is having a lousy cell plan and the risk of early termination fees when they cancel you stecken.Beobachten, like yours in the trash old friend and get a phone, a cell contract for free and change your life with Cellswapper.com (3.05)

Spore – New Mobile Phase

MSCE5. Spore – Cell Phase NEW (03:59)

Spore – Cell Phase

MSCE5 Spore – Cell Phase (01:46)

Training for the company and staff

professionalism, competence and constant updating are three elements of a successful company in every industry and every level

From: Martinal Businessl. March 10, 2011 The promotion of employee presenteeism – Keep it at work physically and mentally

In recent years the conditions “ ” “ employee commitment and employee withdrawal & # 8221 ., have emerged to more fully describe the employees ’ s motivation and commitment to their work A dedicated staff is as passionate about their work and emotional

From: Jack Stanleyl Businessl March 10, 2011 and Makita Woodworking . joinery tools

Since its first corded electric planer Makita power tools to make an industrial power tools company with a strong history of hard and efficient tools for woodworking been

From: Diane Wilsonl Businessl March 10, 2011 Seal the happiness in

your life now with your locksmithing If you are concerned about the security of your assets, try to find the best security locksmith company a bit of a challenge

From:. jacksontbsl Businessl March 10, 2011 As on the right track Stay with your company logo model

most if not all organizations in these days of a mission statement published, which should explain their rationale. It is also true that most if not all organizations today “suffer from Mission Statement Drift ‘ .?. Why is that there could be a number of reasons, however, suffers Organisations

From: John Simmonsl Businessl March 10, 2011 BMI calculation

The Body Mass Index (BMI) is a mathematical formula widely accepted that doctors and nutritionists used for years to determine whether a person in the parameters is a normal level of health of body fat, since these computers are now such an online presence everywhere

From:. mohanchenl Businessl March 10, 2011 payday loan . People with Bad Credit

payday loan is the easiest way to get money in an instant These types of loans are available almost everywhere in the United States

From:. kellyyoungl Businessl March 10, 2011 Business Survival Rule Number .! – Provide or perish

provision and SurviveVon Mike Pagan – “Which industry do you specialize in” Straight Talking Business Focused Professional Speaker Many management consultants and business coaches are asked the question or rather said ‘I want a consultant who Joey has Singerl Businessl March 10, 2011 Current News on Orfgen, AAU and VTG

Orofino Gold Corp. optioned several properties in Colombia

From >, Signed by: Justinl Businessl 15 August 2010 Health and medical announcements PROT, and AZN CBLI

PROTEONOMIX, focuses on the development of therapeutics INC to the use of human cells and their derivatives

Basic By: Justinl Businessl 15 August 2010 Company News from EQLB, cot, and ROX

EQ Labs, Inc. Sales for the six month period that ended on June 30, 2010 sales increased by 40% over the previous year.

From: Justinl Businessl 15 August 2010 Stock information on EVCA, TSLA and ESLR from CRWE Finance

EVCARCO recently reported that the Board has completed the expansion of its operations in South America

Approved by:. Justinl Businessl 15 August 2010 Latest reports from CRWE, KMP and ETE

Crown Equity Holdings, Inc. reported its financial information for the 6-month period ending June 30, 2010

From:. Justinl Businessl 15 August 2010 update on MSLP and EVCA from CRWE Finance

muscle pharm Corporation reported that the National Association of People with AIDS calls for the admission of MSLP s Recon nutritional supplements on the New York State Medicaid list of prescription drugs

From:. Justinl Businessl 15 August 2010 Current News on MSLP, and MJN RELV

muscle pharm Corporation recently reported a distribution agreement with Sportika Export Inc.

From: Justinl Businessl 15 August 2010 Good news from Orfgen, MVG and APC

Good news from Orfgen, MVG and APC reported CRWE Finance

From: Justinl Businessl 13 August 2010 Add Comment Your : Verification Code: * Send your articles here

/>

Sign up today Advertise Article View / Edit items View / Edit Q & A Edit Your Account page authors statistics Personal Edit My Account View / Edit Q & A Justin has 143 Print online Contact Author Article Send to friend Re-publish articles Articles Category All Categories Arts Automotive Beauty Business Careers Computers Education Finance Food & Beverage Health Hobbies Home and Family Home Improvement Internet Law Marketing News and Society Relations Self Improvement Shopping Spirituality Sports and Fitness Technology Travel Writing agriculture Business Ask an Expert Business Ideas Business Opportunities Corporate Customer Service Entrepreneurship Ethics Franchise Fundraising Home Business Human Resources Industrial International Business Leadership Management Negotiating Networking Non Profit Organizations Online Business Outsourcing Organizational Presentation Project Management Aktiengesellschaft Public Relations Sales Six Sigma Small Business Strategic Planning Team Building Training]]> Mobile version Webmaster Promoting Use of this Web site constitutes acceptance of the User Agreement and Privacy Policy | User published content is under a Creative Commons License
reserved Copyright © 2005-2011 Free Articles by ArticlesBase.com, All rights ..

Categories: Uncategorized Tags: Life, MNTA, PROT, updates

Recent reports for PROT, LIFE, and MNTA

March 9th, 2011 Comments off

Recent reports for PROT, LIFE, and MNTA

{image}

Recent reports for PROT, LIFE, and MNTA

Free Online Articles Directory

ABAnswers

0 && $ .browser.msie ) {
var ie_version = parseInt($ .browser.version);
if(ie_version

via

Hello

Password

Lost ?

Home Page > Business > Recent reports for PROT, LIFE, and MNTA

Recent reports for PROT, LIFE, and MNTA

Edit Article |

Posted: Aug 11, 2010 |Comments: 0
|

crwefinancelogo2

signup3m

Proteonomix Inc (OTC:PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. LIFE systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of .3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference.

LIFE reported their results for its second quarter ending June 30, 2010. Their Non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, recently reported it’s financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of .0 million, compared with a net loss of .8 million for the same period last year. At June 30, 2010, the Company had cash, cash equivalents, and marketable securities of .7 million, compared with .7 million at December 31, 2009. Revenue for the second quarter of 2010 was .8 million, compared to .6 million for the same period last year. The decrease in revenue was due to a decrease in reimbursable manufacturing expenses associated with our M356 program and a decrease in reimbursable expenses associated with our enoxaparin sodium injection program as the ANDA review process approached completion. Research and development expenses for the second quarter of 2010 were .8 million, compared to .7 million for the same period last year. The decrease in research and development expenses principally resulted from a decrease in manufacturing, process development and third-party research costs in support of our M356 program and clinical development costs due to the completion of our M118 Phase 2a clinical trial in June 2009.

MNTA is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Retrieved from “http://www.articlesbase.com/business-articles/recent-reports-for-prot-life-and-mnta-3016112.html”

(ArticlesBase SC #3016112)

Watch your traffic increase just by submitting articles with us, click here to get started.
Liked this article? Click here to publish it on your website or blog, it’s free and easy!

Justin -
About the Author:

Questions and Answers

Ask our experts your Business related questions here…

Ask

200 Characters left

I need to find a poem to send to my recent ex. I need to have God in my life and he is going down a different path. One that is hurting him. I love him but had to end it. He is hurt and needs courage
I am a 43 year old man who recently can not produce sperm. I do not drink, smoke, I eat healthy, and have an active sex life with my wife
I have been recently promoted and my colleague who was also aspiring for the same post now reports into me. He is not interested in working under me, neither has interest to discuss his issues with me

Rate this Article

1
2
3
4
5

0

Feedback

Print

Re-Publish

Source: http://www.articlesbase.com/business-articles/recent-reports-for-prot-life-and-mnta-3016112.html

Article Tags:
biotechnology, nasdaq life, nasdaq mnta, otc prot, stem cells, umbilical cord

Recent reports on PROT, LIFE, and CBLI from CRWE Finance

March 7th, 2011 Comments off

Recent reports on PROT, LIFE, and CBLI from CRWE Finance

{image}

Recent reports on PROT, LIFE, and CBLI from CRWE Finance

Free Online Articles Directory

ABAnswers

0 && $ .browser.msie ) {
var ie_version = parseInt($ .browser.version);
if(ie_version

via

Hello

Password

Lost ?

Home Page > Business > Recent reports on PROT, LIFE, and CBLI from CRWE Finance

Recent reports on PROT, LIFE, and CBLI from CRWE Finance

Edit Article |

Posted: Aug 13, 2010 |Comments: 0
|

crwefinancelogo2

signup3m

Proteonomix Inc (OTC:PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

Life Technologies Corporation (NASDAQ:LIFE) and the University of California at San Diego Moores Cancer Center recntly reported a partnership to use SOLID 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia (CLL), a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

CLL is one of four main types of leukemia, which primarily affects adults averaging 70 years old, and causes a slow increase in the number of white blood cells called B cells in the bone marrow. The cancerous cells spread from the marrow to the blood, and can also affect the lymph nodes and other organs, such as the liver and spleen. CLL eventually causes the bone marrow to fail and weakens the immune system.

LIFE is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) recently reported that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) exercised the .1 million fourth milestone-based option on the Company’s existing contract under the Broad Agency Announcement titled, Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation, for selected tasks in the advanced development of Protectan CBLB502. The value of the contract, originally awarded in September 2008, is .6 million, including an increase in the first milestone-based option, which was exercised in September 2009.

CBLI is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Retrieved from “http://www.articlesbase.com/business-articles/recent-reports-on-prot-life-and-cbli-from-crwe-finance-3035844.html”

(ArticlesBase SC #3035844)

Watch your traffic increase just by submitting articles with us, click here to get started.
Liked this article? Click here to publish it on your website or blog, it’s free and easy!

Justin -
About the Author:

Questions and Answers

Ask our experts your Business related questions here…

Ask

200 Characters left

I need to find a poem to send to my recent ex. I need to have God in my life and he is going down a different path. One that is hurting him. I love him but had to end it. He is hurt and needs courage
I am a 43 year old man who recently can not produce sperm. I do not drink, smoke, I eat healthy, and have an active sex life with my wife
We recently had several accounts charged off due to financial problems. We would like to sell our current home to pay off those accounts. How likely is it that we can get financed for anthr mtg soon

Rate this Article

1
2
3
4
5

0

Feedback

Print

Re-Publish

Source: http://www.articlesbase.com/business-articles/recent-reports-on-prot-life-and-cbli-from-crwe-finance-3035844.html

Article Tags:
cancer, leukimia, medicine, nasdaq cbli, nasdaq life, otc prot, stem cell, therapy

Buy My IOU – Sell Your Government IOU For CASH

Archive

From Startup Dreams to a Cubicle Life

Tony Hayward Gets His Life Back

Combining Long-Term Care with Life Insurance

You Bet Your Life 3

Medical news on PWRM, TEVA, and LIFE

Updates of PROT, and MNTA LIFE

Recent reports for PROT, LIFE, and MNTA

Recent reports on PROT, LIFE, and CBLI from CRWE Finance

Recent Posts

Translator

Feed

Recommended

Categories

Blogroll